Pedro L. Alonso

Last updated

Pedro L. Alonso (born March 18, 1959, in Madrid, Spain), is a physician, epidemiologist, [1] and researcher in diseases that affect vulnerable populations. Based on a multidisciplinary approach, his work focuses mainly on malaria, although he has also studied other infectious diseases. He served as the Director of the Global Malaria Programme at the World Health Organization between 2014 and 2022, and is currently Professor of Global Health at the Faculty of Medicine and Health Science-Hospital Clinic, at the University of Barcelona.

Contents


Education and professional career

Pedro Alonso completed his high school education at the United World College of the Atlantic. [2] [3] After obtaining his medical degree at the Autonomous University of Madrid in 1984, Pedro L. Alonso earned a Masters in Epidemiology and Control of Communicable Diseases at the London School of Hygiene and Tropical Medicine. He then obtained a PhD in medicine in the University of Barcelona. He is also a specialist in Community Medicine and Public Health by the Spanish Ministry of Health.

His professional career began in The Gambia in the 1980s. A study on the validation of verbal autopsies was followed by the scientific assessment of the efficacy of Insecticide Treated Nets (ITNs) as a preventive tool against malaria. The utility of such nets was, at the time, controversial, and the publication of new results in The Lancet [4] was critical for the launching of subsequent studies confirming first evaluations. Based on this evidence, WHO recommended the universal use of ITNs as a vector control tool, since a pillar in the fight against malaria. It is estimated that extensive distribution programs of ITNs can claim responsibility for 69% of the 663 million of averted malaria cases in Subsaharan Africa between 2001 and 2015. [5]

After a short stay at the Instituto de Parasitología “López Neyra”, Consejo Superior de Investigaciones Científicas, in Granada, Spain, Pedro L. Alonso settled in Barcelona in 1991 to head the Epidemiology & Biostatistics Unit at the Hospital Clinic, an institution to which he would remain linked for more than 20 years and where he created and directed the Center for International Health –the first of its kind in a Spanish university hospital.

While in Barcelona, he promoted his first international collaborations, most notably with the Ifakara Health Institute (Tanzania), where along with Dr. Marcel Tanner, he worked in the evaluation of the malaria vaccine SPf66. In collaboration with Dr. Clara Menéndez, Pedro L. Alonso broadened his research field to include malaria prophylaxis in children under 1 year old, evaluation of new malaria control strategies such as intermittent treatment for children and pregnant women, etiology of anemia, and the study of further causes of death and disease in African children including acute respiratory diseases and diarrheas.

With the support of the Hospital Clínic and the University of Barcelona, he founded in 2006 the Barcelona Centre for International Health Research (CRESIB). In this institution he accomplished one of his most renowned works, the contribution to the clinical development and impact assessment of a new malaria vaccine: RTS,S. In collaboration with the Manhiça Health Research Centre in Mozambique, he implemented two proofs of concept that established for the first time the efficacy of the vaccine in infants [6] and children aged 1–4 years. [7] These results opened the door to subsequent assessments and to a Phase 3 clinical trial performed in 11 African research centres. Ultimately, this vaccine received a positive assessment by the European Drugs Agency, in 2015, [8] while the highest expert committees at WHO have recommended that it starts to be utilized, as of 2018, in pilot programs in three African countries. [9]

Apart from his own activities as scientific researcher, Pedro L. Alonso has devoted considerable efforts to facilitate the development of research capacities in Africa, as well as to training new generations of scientists both in Spain and in developing countries. He has directed 24 doctoral dissertations in a variety of fields ranging from basic biology, epidemiology, evaluation of new interventions or clinical development of drugs and vaccines for respiratory and diarrheal diseases, HIV, tuberculosis and malaria.

In regard to the creation of institutions, the foundation of the Manhiça Health Research Centre (CISM) in Mozambique is of particular importance. Launched in 1996 in the context of cooperation agreements between Mozambique and Spain, CISM receives funds from the Spanish Agency for International Cooperation. Pedro L. Alonso was CISM scientific director from 1996 to 2008, year in which the ownership of the centre was trespassed to a fully Mozambican institution: Fundaçao Manhiça. For several years, CISM stood as the only African centre with a demographic surveillance system and pioneered broad clinical studies in Africa. CISM was distinguished in 2008 with the Príncipe de Asturias Award for International Cooperation, with three other African institutions.

This same line of work prompted the foundation of the Barcelona Institute for Global Health (ISGlobal), for which he also served as the first general director. ISGlobal aims to break the vicious circle of poverty and disease with an integrated approach that extracts and implements knowledge through its areas of Training, Policy, and Global Development. At an international level, Pedro L. Alonso participated, together with Dr. Fred Binka, in the creation of the European and Developing Countries Clinical Trial Partnership, a joint endeavor by European and African countries with the objective of promoting and funding the development of new tools against malaria, tuberculosis and HIV.

As a result of a paradigm shift that makes of malaria eradication a shared objective by the international community, Pedro L. Alonso led, jointly with Dr. Marcel Tanner, the Malaria Eradication Research Agenda (malERA) initiative that defined research and future development needs for malaria eradication. Results of malERA were published in 2011 [10] in PLoS Medicine and led to the creation of the Malaria Eradication Scientific Alliance (MESA). [11]

Between October 2014 and March 2022, Pedro L. Alonso was the Director of the Global Malaria Programme at the WHO, and was responsible for coordinating efforts to control and eliminate malaria and establish norms, technical guidelines and policies to support countries affected by this disease.

Beyond the malaria field, Pedro L. Alonso, Ciro de Quadros, and Christopher Elias led the Committee that developed the Global Vaccine Action Plan, approved by the World Health Assembly in 2012. Dr. Alonso has been a member of numerous expert committees at WHO, the European Union, Medicines for Malaria Venture, TDR or the Spanish Ministry of Health, among others.

Current position

Pedro L. Alonso is currently Professor of Global Health at the Faculty of Medicine and Health Science-Hospital Clinic, at the University of Barcelona.

Publications and awards

Pedro L. Alonso is included in the "top 20" list of most cited authors in the malaria field [12] and also is on list of the 50 most influential people in the vaccines field. [13]

Throughout his career, he has published more than 350 articles and has received, among other awards, the Gran Cruz de la Orden Civil de Sanidad (Ministry of Health, Madrid, Spain), the Red Cross and Red Crescent Golden Medal (Barcelona, Spain), the Josep Trueta medal (Generalitat of Catalonia), the Balmis award (Ministry of Defense, Madrid, Spain), the Ronald Ross Medal (London School of Hygiene and Tropical Medicine, UK), the BBVA Foundation Frontiers of Knowledge Award (Spain), and the Carlos IV award (Royal National Academy of Medicine, Spain). He is an International Honorary Fellow of the American Society of Tropical Medicine and Hygiene.

Since 2008, Pedro L. Alonso is Professor of Global Health at the University of Barcelona and has been awarded Doctor Honoris Causa by the Universidad Europea de Madrid and the Universidad Rey Juan Carlos

Personal life

Pedro L. Alonso is married to Clara Menéndez, a researcher expert in malaria in pregnancy. They have three children, Yara, Miguel and Sofía.

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Mosquito-borne infectious disease

Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected Anopheles mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

Since October 2018, the Center for Global Infectious Disease Research has been part of the Seattle Children's Research Institute. At the time of the merger, CID Research had 166 scientists. Its mission was to eliminate the world's most devastating infectious diseases through leadership in scientific discovery. The organization's research labs were in the South Lake Union area of Seattle, WA. The institute's research focused on four areas of infectious disease: HIV/AIDS, malaria, tuberculosis (TB), and Emerging & Neglected Diseases (END) like African sleeping sickness, leishmaniasis, Chagas disease, and toxoplasmosis. CID Research was engaged in early stages of the scientific pipeline including bench science and malaria clinical trials and has expertise in immunology, vaccinology, and drug discovery.

Sir Richard George Andrew Feachem, KBE, FREng is professor of global health at both the University of California, San Francisco, and the University of California, Berkeley, and director of the Global Health Group at UCSF Global Health Sciences. He is also a visiting professor at the University of London and an honorary professor at the University of Queensland.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">PATH (global health organization)</span> Global health nonprofit

PATH is an international, nonprofit global health organization. PATH is based in Seattle with 1,600 employees in more than 70 countries around the world. Its president and CEO is Nikolaj Gilbert, who is also the Managing Director and CEO of Foundations for Appropriate Technologies in Health (FATH), PATH's Swiss subsidiary. PATH focuses on six platforms: vaccines, drugs, diagnostics, devices, system, and service innovations.

Malaria vaccines are vaccines that prevent malaria, a mosquito-borne infectious disease which annually affects an estimated 247 million people worldwide and causes 619,000 deaths. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

<span class="mw-page-title-main">Eradication of infectious diseases</span> Elimination of a disease from all hosts

The eradication of infectious diseases is the reduction of the prevalence of an infectious disease in the global host population to zero.

<span class="mw-page-title-main">African Malaria Network Trust</span> Non-governmental organization

The African Malaria Network Trust (AMANET) is a pan-African international NGO headquartered in Dar es Salaam, Tanzania. It originally started its activities as African Malaria Vaccine Testing Network (AMVTN) in 1995 with the primary goal of preparing Africa in planning and conducting malaria vaccine trials. In order to widen the scope in malaria interventions, AMVTN was succeeded by AMANET on 14 March 2002. Although the primary goal of AMANET has remained malaria vaccine development, the organization in its expanded role includes other intervention measures such as antimalaria drugs and vector control.

<span class="mw-page-title-main">Mirta Roses Periago</span> Argentine epidemiologist

Mirta Roses Periago is an Argentine epidemiologist who served as Director of the Pan American Health Organization (PAHO) from 2003 until 2013.

The American Society of Tropical Medicine and Hygiene (ASTMH) is an Arlington, Virginia-based non-profit organization of scientists, clinicians, students and program professionals whose longstanding mission is to promote global health through the prevention and control of infectious and other diseases that disproportionately afflict the global poor. ASTMH members work in areas of research, health care and education that encompass laboratory science, international field studies, clinical care and country-wide programs of disease control. The current organization was formed in 1951 with the amalgamation of the American Society of Tropical Medicine, founded in 1903, and the National Malaria Society, founded in 1941.

Global Health Initiatives (GHIs) are humanitarian initiatives that raise and disburse additional funds for infectious diseases – such as AIDS, tuberculosis, and malaria – for immunizations and for strengthening health systems in developing countries. GHIs classify a type of global initiative, which is defined as an organized effort integrating the involvement of organizations, individuals, and stakeholders around the world to address a global issue.

<span class="mw-page-title-main">RTS,S</span> Malaria vaccine

RTS,S/AS01 is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved. As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. 18 million doses have been allocated for 2023-2025. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.

Chetan Eknath Chitnis is an Indian scientist in the field of malaria research. He is the head of the Malaria Parasite Biology and Vaccines Unit at the Institut Pasteur in Paris and an elected fellow of the Indian Academy of Sciences (2009) as well as Indian National Science Academy (2014). He received the Shanti Swaroop Bhatnagar Award in 2004 and the Infosys Prize in Life Sciences 2010. Chitnis is the former principal investigator of the malaria research group at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in New Delhi.

<span class="mw-page-title-main">Jeremy Farrar</span> British medical researcher

Sir Jeremy James Farrar is a British medical researcher who serves as Chief Scientist at the World Health Organization since 2023. He was previously the director of The Wellcome Trust from 2013 to 2023 and a professor of tropical medicine at the University of Oxford.

Mundo Sano, or Fundación Mundo Sano, is a scientific, nongovernmental foundation in Argentina working for the prevention and control of communicable diseases such as dengue fever, Chagas disease, malaria, leishmaniasis and soil-transmitted helminthiasis. Its main objective is to facilitate equal access to health and welfare among people who are vulnerable to these otherwise avoidable diseases, mainly by promoting strategic policies for the improvement of the quality of life of affected communities.

The Malaria Eradication Scientific Alliance (MESA) is an organization founded on the research carried out by the Malaria Eradication Research Agenda (malERA). "malERA" was a project carried out by the scientific community to identify the steps and future research that must be done in order to eradicate malaria. It was created after the Malaria Forum in 2007, hosted by the Bill and Melinda Gates Foundation, reestablished malaria eradication as a long-term goal. "malERA" first launched in 2008, and resulted in a research and development agenda which was published in a PLoS Medicine magazine in 2011. MESA was formed in 2012 to continue the goals of malERA through research and development of methods to fight malaria.

Peter Gottfried Kremsner is a specialist in tropical medicine and Full Professor at the University of Tübingen, Germany. Since 1992 he has been leading the Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon, now as president.

<span class="mw-page-title-main">Oriol Mitjà</span> Catalan researcher

Oriol Mitjà i Villar is a Catalan-born Spanish researcher and consultant physician in internal medicine and infectious diseases with expertise in poverty-related tropical diseases. He has conducted research at the Lihir Medical Centre in Papua New Guinea since 2010 on new diagnostic and therapeutic tools to eradicate yaws. He was awarded the Princess of Girona Award in the scientific research category. Currently at the Germans Trias i Pujol Research Institute, Mitjà is conducting research on SARS-CoV-2 coronavirus disease (COVID-19) and strategies to control the infection at a community level.

Dr. Winnie Mpanju-Shumbusho is a Tanzanian paediatrician and public health leader who until December 31, 2015, served as World Health Organization (WHO) Assistant Director General for HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases based in Geneva, Switzerland. From 2016 to 2019, she served as board chair of RBM Partnership To End Malaria. Before joining WHO in 1999, Mpanju-Shumbusho was Director General of The East, Central and Southern African Health Community (ECSA-HC) formerly known as the Commonwealth Regional Health Community for East, Central and Southern Africa (CRHC-ECSA).

Halidou Tinto is a Professor of parasitology and global health scientist with research that has contributed to understanding and combating malaria in Sub-Saharan Africa. Tinto founded the Clinical Research Unit of Nanaro (CRUN) in Burkina Faso as part of the Institut de Recherche en Sciences de la Santé (IRSS). Tinto is now the Regional Director of the IRSS, and throughout his career he has contributed to the study of antimalarial drug resistance and the development of malaria vaccines.

References

  1. ↑ "Message from Pedro Alonso, Director GMP: Welcoming Dr Fred Binka to WHO | MalariaWorld". malariaworld.org. Retrieved 2019-02-03.
  2. ↑ "PEDRO LUÍS ALONSO Curriculum Vitae" (PDF).
  3. ↑ "The International School of Geneva and the United World Colleges in the early years of the International Baccalaureate".
  4. ↑ Alonso PL, Lindsay SW, Armstrong JR, Conteh M, Hill AG, David PH, Fegan G, de Francisco A, Hall AJ, Shenton FC (1991). "The effect of insecticide-treated bed nets on mortality of Gambian children". Lancet. 337 (8756): 1499–502. doi:10.1016/0140-6736(91)93194-e. PMID   1675368. S2CID   13357255.
  5. ↑ World Health Organization (2015). World Malaria Report. Geneva: WHO.
  6. ↑ Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, Lievens M, Vekemans J, Sigauque B, Dubois MC, Demoitie MA, Sillman M, Savarese B, McNeil JG, Macete E, Ballou WR, Cohen J, Alonso PL (2007). "Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/Iib tria". Lancet. 370 (9598): 1543–1551. doi:10.1016/s0140-6736(07)61542-6. PMID   17949807. S2CID   19372191.
  7. ↑ Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J (2004). "Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial". Lancet. 364 (9443): 1411–20. doi:10.1016/s0140-6736(04)17223-1. PMID   15488216. S2CID   10373545.
  8. ↑ "First malaria vaccine receives positive scientific opinion from EMA". 17 September 2018.
  9. ↑ "Q&A on the malaria vaccine implementation programme (MVIP)".
  10. ↑ Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Fenton Hall B, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M (2011). "A Research Agenda to Underpin Malaria Eradication". PLOS ONE. 8 (1): e1000406. doi: 10.1371/journal.pmed.1000406 . PMC   3026687 . PMID   21311579.
  11. ↑ "Malaria Eradication Scientific Alliance".
  12. ↑ "Publication Analysis 2007-2013". Archived from the original on 2017-06-13. Retrieved 2017-06-12.
  13. ↑ "Who are the most influential people in vaccines?" (PDF). Archived from the original (PDF) on 2014-03-08. Retrieved 2017-06-12.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.